Join Hudson Institute Senior Fellow Urška Petrovčič and expert panelists David Kappos, Erika Lietzan, and Senior Fellow Adam Mossoff for a discussion on the role of drug patents as a driver of innovation in healthcare and the importance of evidence-based policymaking in patent law.
Congress and federal agencies have been holding hearings, issuing reports, and considering various policy measures on whether drug patents raise prices in healthcare. These legislative and policy efforts have been driven by reports published by I-MAK of massively high numbers of patents on specific drugs. Yet as a recent Hudson Institute policy memo by Adam Mossoff explains, I-MAK’s patent numbers are unreliable and its private database is unverifiable. Please join our expert panel for a discussion on the policy debate over drug patents and the importance of evidence-based policymaking by Congress and agencies.
Watch on Hudson.org: [ Ссылка ]
